SLS

4.87

2.99% -0.15

Dopo l'orario di chiusura: 4.88 0.010 +0.21%

Sellas Life Sciences Group Inc (SLS)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché SLS Giù? Forum Previsione Frazionamento azionario

Precedente Chiudi:

$5.02

Aprire:

$5.05

Volume 24 ore:

2.84M

Relative Volume:

0.47

Capitalizzazione di mercato:

$898.67M

Reddito:

Utile/perdita netta:

$-26.86M

Rapporto P/E:

-19.81

EPS:

-0.2458

Flusso di cassa netto:

$-28.39M

1 W Prestazione:

-0.20%

1M Prestazione:

+17.92%

6M Prestazione:

+189.88%

1 anno Prestazione:

+184.80%

Intervallo 1D:

$4.825

$5.055

Intervallo di 1 settimana:

$4.655

$5.235

Portata 52W:

$1.36

$6.14

Sellas Life Sciences Group Inc Stock (SLS) Company Profile

Nome

Sellas Life Sciences Group Inc

Settore

Healthcare (1106)

Industria

Biotechnology (615)

Telefono

(646) 200-5278

Indirizzo

7 TIMES SQUARE, NEW YORK, NY

Dipendente

Cinguettio

Prossima data di guadagno

2026-05-12

Ultimi documenti SEC

SLS's Discussions on Twitter

Compare SLS vs VRTX, REGN, ARGX, ALNY, ONC

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
SLS Sellas Life Sciences Group Inc	4.87	926.35M	0	-26.86M	-28.39M	-0.2458
VRTX Vertex Pharmaceuticals Inc	424.36	109.34B	12.32B	4.34B	3.19B	16.86
REGN Regeneron Pharmaceuticals Inc	702.27	74.35B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	794.70	50.44B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	301.11	39.78B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	297.49	33.02B	5.36B	287.73M	924.18M	2.5229

Sellas Life Sciences Group Inc Stock (SLS) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2021-07-21	Iniziato	Cantor Fitzgerald	Overweight
2018-11-01	Iniziato	Oppenheimer	Outperform
2018-04-02	Iniziato	H.C. Wainwright	Buy
2018-03-19	Aggiornamento	Maxim Group	Hold → Buy

Sellas Life Sciences Group Inc Borsa (SLS) Ultime notizie

May 05, 2026

SLS stock kicks off week in green: CEO flags role in EU biotech policy talks that could impact drug approvals - MSN

May 05, 2026

May 04, 2026

SLS Stock Kicks Off Week In Green: CEO Flags Role In EU Biotech Policy Talks That Could Impact Drug Approvals - Stocktwits

May 04, 2026

May 03, 2026

SLS stock slips after-hours as cancer pipeline silence frustrates retail — China licensing fight now in spotlight - MSN

May 03, 2026

May 02, 2026

SLS Stock Tests $5 Again: Retail Targets ‘No’ Vote On 20M Share Dilution Push Before AML Trial Results - Stocktwits

May 02, 2026

SLS stock gains momentum: NVDA, MSFT investor loads up ahead of AML trial milestone trigger - MSN

May 02, 2026

May 01, 2026

Sellas Life Sciences draws significant retail buzz as traders eye REGAL phase 3 catalyst – SLS stock soars 15% - MSN

May 01, 2026

SLS News | SELLAS LIFE SCIENCES GROUP I (NASDAQ:SLS) - ChartMill

May 01, 2026

Apr 30, 2026

SLS stock sparks retail buzz ahead of AACR presentation on experimental cancer therapy - MSN

Apr 30, 2026

SLS stock jumps premarket: US investor Dagco boosts stake by 78% ahead of fresh cancer drug data reveal - MSN

Apr 30, 2026

SLS Forecast, Price Target & Analyst Ratings | SELLAS LIFE SCIENCES GROUP I (NASDAQ:SLS) - ChartMill

Apr 30, 2026

Apr 29, 2026

SLS stock jumps overnight: ‘potent’ AML drug data ahead of cancer summit fuels fresh momentum - MSN

Apr 29, 2026

SELLAS Life Sciences Group (SLS) price target increased by 15.38% to 10.20 - MSN

Apr 29, 2026